A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Event-driven primary disease-free survival ('DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ('PDAC”) is anticipated in 1H 2026Fewer ...

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...

March 12, 2026 7:30am EDT Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ...

The next question researchers want to answer is whether urine-derived lymphocytes can actually help inform responses to ...

US FDA accepts and grants priority review status to AstraZeneca and Daiichi Sankyo’s sBLA for Enhertu to treat adult patients with HER2-positive early breast cancer: Cambridge, ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...

China: A neoadjuvant combination regimen comprising chemotherapy, targeted therapy, and immunotherapy has demonstrated significant clinical benefit in patients with resectable ...